Pardes Biosciences, Inc. (PRDS)
| Market Cap | 372.99M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -12.89M |
| Shares Out | 25.76M |
| EPS (ttm) | -0.47 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 27,329 |
| Open | 14.02 |
| Previous Close | 13.95 |
| Day's Range | 13.86 - 14.48 |
| 52-Week Range | 9.69 - 17.76 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About PRDS
As of December 23, 2021, FS Development Corp. II was acquired by FS Development Corp. II, in a reverse merger transaction. FS Development Corp. II does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2020 and is based in San Francisco, California.
News
Pardes Biosciences to Present at J.P. Morgan Healthcare Conference
CARLSBAD, Calif., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential novel direct-acting, oral antiv...
Pardes Biosciences Debuts as a Publicly Traded Company Focused on Oral Antiviral Therapies to Potentially Treat and P...
Ongoing Phase I trial shows potential for stand-alone, unboosted agent against COVID-19
FSII and Pardes Biosciences Move Towards Merger With the Goal of Tackling COVID-19 via an Oral Antiviral for Treatmen...
SAN FRANCISCO & LARKSPUR, Calif.--(BUSINESS WIRE)--FSII and Pardes Biosciences move towards merger with the goal of tackling COVID-19 via an oral antiviral.
FS Development Corp. II Announces Effectiveness of Registration Statement for Proposed Business Combination with Pard...
LARKSPUR, Calif.--(BUSINESS WIRE)--FS Development Corp. II announces effectiveness of registration statement for proposed business combination with Pardes
Pardes Biosciences and FS Development Corp. II Announce Merger Agreement Creating Publicly Listed Biopharmaceutical C...
CARLSBAD, Calif. & LARKSPUR, Calif.--(BUSINESS WIRE)--Pardes Biosciences and FS Development Corp. II announce merger agreement creating publicly listed company advancing oral antiviral drugs.
2 New Healthcare SPACs Worth Adding to Your Watch List
SPAC-mania is in full swing, and the healthcare sector is starting to pop with new offerings.
FS Development Corp. II, Sponsored by Foresite Capital, Announces Pricing of Upsized $175 Million Initial Public Offe...
SAN FRANCISCO--(BUSINESS WIRE)-- #lifesciences--FS Development Corp. II announced today that it priced its initial public offering of 17,500,000 shares of Class A common stock at $10.00 per share.